The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients

BACKGROUND: Immune checkpoints inhibitors (ICIs) have emerged as a treatment option for several malignancies. Nivolumab, pembrolizumab, nivolumab plus ipilimumab, and atezolizumab plus bevacizumab have been approved for the management of advanced‐stage hepatocellular carcinoma (HCC). We aimed to sys...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Ziogas, Ioannis A., Evangeliou, Alexandros P., Giannis, Dimitrios, Hayat, Muhammad H., Mylonas, Konstantinos S., Tohme, Samer, Geller, David A., Elias, Nahel, Goyal, Lipika, Tsoulfas, Georgios
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2021
Aiheet:
Hepatobiliary
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176986/
https://ncbi.nlm.nih.gov/pubmed/33314549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13638
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia